CAP5610 HW3 – Tree Ensembles & SHAP Interpretation

Prepared by: Leandro Gonzalez

Date: 2025-10-08

This report summarises the HW3 workflow: benchmarking six tree ensembles, interpreting the winners with SHAP, and linking the findings back to lessons from large-scale tabular ML practice.

# 1. Algorithms, Approaches, and Tools

**Decision Tree —** What: A single CART-style tree that recursively partitions the feature space. How: Each split minimises impurity (Gini/MSE) with depth controlled via leaf-size constraints. Application: Baseline classifier/regressor in Tasks 1 and 3.

**Random Forest —** What: An ensemble of decorrelated trees aggregated by voting/averaging. How: Bootstrap sampling and feature subsampling reduce variance while maintaining interpretability. Application: Delivered the best cancer classifier in Task 1 and serves as a regression baseline.

**Gradient Boosting Machine —** What: Sequential additive trees fit residuals of prior learners. How: Optimises differentiable loss with learning-rate-scaled depth-limited trees. Application: Produced the strongest drug-response regressor (Task 3) and underpins Task 4 explanations.

**XGBoost —** What: Optimised gradient boosting with histogram splits and regularisation. How: Uses second-order gradients, shrinkage, and column caching for high-dimensional speed. Application: Benchmarked for both classification and regression sweeps.

**LightGBM —** What: Leaf-wise histogram boosting with gradient-based sampling. How: Chooses the split with maximal gain while regularising via leaf counts and feature bundling. Application: Provides a fast alternative ensemble for Tasks 1 and 3.

**CatBoost —** What: Boosting with ordered target statistics and symmetric trees. How: Employs oblivious trees and Bayesian encodings to stabilise high-cardinality features. Application: Evaluated alongside other ensembles; competitive without heavy tuning.

**Polars/Pandas Ingestion —** What: Columnar dataframe readers for wide genomic matrices. How: Prefers Polars CSV reader and falls back to pandas; NumPy variance pruning trims features. Application: Reduces memory footprint ahead of modelling in both tasks.

**Joblib Parallelism —** What: Parallel model sweeps wrapped with tqdm progress bars. How: Runs estimators concurrently while logging timing/memory statistics. Application: Accelerates classifier/regressor sweeps and feeds the automation layer.

**SHAP Interpretability —** What: Feature attribution tuned for tree ensembles. How: Samples backgrounds, caches outputs, and renders contribution plots for the winning models. Application: Generates per-cancer and per-drug explanations (Tasks 2 and 4).

**Experiment Automation —** What: Checkpointed progress tracker with timing logs. How: Writes JSON state, caches datasets/models, and resumes safely after interruptions. Application: Keeps long notebook runs reproducible and debuggable.

# 2. Results

**Table 1. Task 1 Classifier Benchmark (Accuracy & Macro-F1)**

Description: Every ensemble was tuned identically on an 80/20 split before being scored.

Observation: RandomForest edges out the boosted models by roughly 0.002 macro-F1 while matching their accuracy.

Conclusion: I kept the forest for SHAP work because its lead persisted across reruns.

|  |  |  |
| --- | --- | --- |
| Model | Test\_Accuracy | Test\_F1\_Macro |
| RandomForest | 0.974308 | 0.974226 |
| LightGBM | 0.972332 | 0.972386 |
| XGBoost | 0.970356 | 0.970409 |
| GBM | 0.960474 | 0.960552 |
| DecisionTree | 0.930830 | 0.930806 |
| CatBoost | 0.207510 | 0.068740 |

**Table 2. Task 2 SHAP Top Features (Top 5 per Cancer Type)**

Description: Leading SHAP-ranked genes when the RandomForest predicts each cancer class.

Observation: Each tumour type leans on a distinct expression signature (e.g., ENSG00000203499.9 for KIRC).

Conclusion: The classifier is not conflating signals between cancers, which justified deeper interpretation.


|  |  |  |  |
| --- | --- | --- | --- |
| CancerType | Rank | Feature | Mean|SHAP| |
| KIRC | 1 | ENSG00000224490.4 | 0.022562 |
| KIRC | 2 | ENSG00000203499.9 | 0.021265 |
| KIRC | 3 | ENSG00000213373.6 | 0.014451 |
| KIRC | 4 | ENSG00000178803.9 | 0.010911 |
| KIRC | 5 | ENSG00000185904.10 | 0.010386 |
| LUAD | 1 | ENSG00000166770.9 | 0.015053 |
| LUAD | 2 | ENSG00000203499.9 | 0.013383 |
| LUAD | 3 | ENSG00000224090.1 | 0.012925 |
| LUAD | 4 | ENSG00000204949.7 | 0.012541 |
| LUAD | 5 | ENSG00000224984.1 | 0.012051 |
| LUSC | 1 | ENSG00000224984.1 | 0.018539 |
| LUSC | 2 | ENSG00000214772.2 | 0.017312 |
| LUSC | 3 | ENSG00000224090.1 | 0.013498 |
| LUSC | 4 | ENSG00000203499.9 | 0.012778 |
| LUSC | 5 | ENSG00000224961.1 | 0.009923 |
| PRAD | 1 | ENSG00000152931.7 | 0.017569 |
| PRAD | 2 | ENSG00000166770.9 | 0.015745 |
| PRAD | 3 | ENSG00000224087.1 | 0.015599 |
| PRAD | 4 | ENSG00000224090.1 | 0.015194 |
| PRAD | 5 | ENSG00000224614.1 | 0.013909 |
| THCA | 1 | ENSG00000166770.9 | 0.013091 |
| THCA | 2 | ENSG00000224020.1 | 0.012440 |
| THCA | 3 | ENSG00000197251.3 | 0.012402 |
| THCA | 4 | ENSG00000203497.2 | 0.012357 |
| THCA | 5 | ENSG00000203499.9 | 0.010978 |

**Figure 1. Force-style contributions — KIRC vs patient TCGA-39-5011-01A**

Description: Contribution bars summarise how the top genes push the prediction towards or away from the class.

Observation: Dominant drivers include ENSG00000233639.4, ENSG00000269707.1, ENSG00000253563.2; their signs mirror the SHAP rankings in Table 2.

Conclusion: Patient-level explanations stay faithful to the population trends, reinforcing confidence in the RandomForest outputs.




**Figure 2. Force-style contributions — LUAD vs patient TCGA-39-5011-01A**

Description: Contribution bars summarise how the top genes push the prediction towards or away from the class.

Observation: Dominant drivers include ENSG00000255794.5, ENSG00000226137.5, ENSG00000272894.4; their signs mirror the SHAP rankings in Table 2.

Conclusion: Patient-level explanations stay faithful to the population trends, reinforcing confidence in the RandomForest outputs.




**Figure 3. Force-style contributions — LUSC vs patient TCGA-39-5011-01A**

Description: Contribution bars summarise how the top genes push the prediction towards or away from the class.

Observation: Dominant drivers include ENSG00000226137.5, ENSG00000272894.4, ENSG00000224984.1; their signs mirror the SHAP rankings in Table 2.

Conclusion: Patient-level explanations stay faithful to the population trends, reinforcing confidence in the RandomForest outputs.




**Figure 4. Force-style contributions — PRAD vs patient TCGA-39-5011-01A**

Description: Contribution bars summarise how the top genes push the prediction towards or away from the class.

Observation: Dominant drivers include ENSG00000259793.1, ENSG00000240990.8, ENSG00000258414.1; their signs mirror the SHAP rankings in Table 2.

Conclusion: Patient-level explanations stay faithful to the population trends, reinforcing confidence in the RandomForest outputs.




**Figure 5. Force-style contributions — THCA vs patient TCGA-39-5011-01A**

Description: Contribution bars summarise how the top genes push the prediction towards or away from the class.

Observation: Dominant drivers include ENSG00000255794.5, ENSG00000236130.1, ENSG00000267259.1; their signs mirror the SHAP rankings in Table 2.

Conclusion: Patient-level explanations stay faithful to the population trends, reinforcing confidence in the RandomForest outputs.



**Table 3. Task 3 Regressor Benchmark (MAE, MSE, RMSE, R²)**

Description: Gradient boosting variants, forests, and single trees evaluated on LN\_IC50.

Observation: GradientBoostingRegressor delivers the lowest RMSE (3.2056) with marginal MAE gains over CatBoost.

Conclusion: GBMReg became the workhorse for drug-response interpretation in Task 4.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Model | MAE | MSE | RMSE | R2 |
| GBMReg | 2.772541 | 10.275986 | 3.205618 | 0.009682 |
| CatBoostReg | 2.774567 | 10.303430 | 3.209896 | 0.007037 |
| XGBReg | 2.884384 | 11.136548 | 3.337147 | -0.073252 |
| LGBMReg | 2.901739 | 11.292500 | 3.360431 | -0.088281 |
| DecisionTreeReg | 2.903208 | 11.307313 | 3.362635 | -0.089709 |
| RandomForestReg | 2.903994 | 11.323066 | 3.364976 | -0.091227 |

**Table 4. Task 4 SHAP Top Features (Top 5 per Drug)**

Description: Per-drug SHAP rankings distilled to the five strongest genomic drivers.

Observation: Navitoclax, for example, remains dominated by BCL2L1—matching its mechanism of action.

Conclusion: These profiles confirm the regressor is capturing pharmacologically meaningful signals.

|  |  |  |  |
| --- | --- | --- | --- |
| Drug | Rank | Feature | Mean|SHAP| |
| A375|Nutlin-3a (-) | 1 | num\_\_DDB2 | 0.057654 |
| A375|Nutlin-3a (-) | 2 | num\_\_HDAC11 | 0.051277 |
| A375|Nutlin-3a (-) | 3 | num\_\_ELMO1 | 0.049495 |
| A375|Nutlin-3a (-) | 4 | num\_\_BCL2L1 | 0.049034 |
| A375|Nutlin-3a (-) | 5 | num\_\_ITGA3 | 0.047449 |
| A498|PD0325901 | 1 | num\_\_BCL2L1 | 0.083484 |
| A498|PD0325901 | 2 | num\_\_DAAM1 | 0.070761 |
| A498|PD0325901 | 3 | num\_\_IKZF1 | 0.058907 |
| A498|PD0325901 | 4 | num\_\_EEF2 | 0.049513 |
| A498|PD0325901 | 5 | num\_\_CD81 | 0.049142 |
| ATN-1|Camptothecin | 1 | num\_\_IKZF1 | 0.294840 |
| ATN-1|Camptothecin | 2 | num\_\_DEF6 | 0.134413 |
| ATN-1|Camptothecin | 3 | num\_\_EEF2 | 0.076803 |
| ATN-1|Camptothecin | 4 | num\_\_AGAP2 | 0.073759 |
| ATN-1|Camptothecin | 5 | num\_\_BID | 0.064116 |
| CAL-39|Nutlin-3a (-) | 1 | num\_\_BCL2L1 | 0.121096 |
| CAL-39|Nutlin-3a (-) | 2 | num\_\_IKZF1 | 0.094304 |
| CAL-39|Nutlin-3a (-) | 3 | num\_\_GSTM1 | 0.093464 |
| CAL-39|Nutlin-3a (-) | 4 | num\_\_CKS1B | 0.084514 |
| CAL-39|Nutlin-3a (-) | 5 | num\_\_EEF2 | 0.067877 |
| CAL-54|MG-132 | 1 | num\_\_BCL2L1 | 0.134463 |
| CAL-54|MG-132 | 2 | num\_\_CKS1B | 0.079628 |
| CAL-54|MG-132 | 3 | num\_\_EEF2 | 0.075196 |
| CAL-54|MG-132 | 4 | num\_\_IKZF1 | 0.067974 |
| CAL-54|MG-132 | 5 | num\_\_BAX | 0.061141 |
| CAL-54|Palbociclib | 1 | num\_\_BCL2L1 | 0.134463 |
| CAL-54|Palbociclib | 2 | num\_\_CKS1B | 0.079628 |
| CAL-54|Palbociclib | 3 | num\_\_EEF2 | 0.075196 |
| CAL-54|Palbociclib | 4 | num\_\_IKZF1 | 0.067974 |
| CAL-54|Palbociclib | 5 | num\_\_BAX | 0.061141 |
| COR-L303|Docetaxel | 1 | num\_\_EEF2 | 0.139853 |
| COR-L303|Docetaxel | 2 | num\_\_BCL2L1 | 0.090427 |
| COR-L303|Docetaxel | 3 | num\_\_FGF23 | 0.051714 |
| COR-L303|Docetaxel | 4 | num\_\_ITGA3 | 0.049809 |
| COR-L303|Docetaxel | 5 | num\_\_CARM1 | 0.049422 |
| COR-L311|MG-132 | 1 | num\_\_BIRC3 | 0.087079 |
| COR-L311|MG-132 | 2 | num\_\_EEF2 | 0.073385 |
| COR-L311|MG-132 | 3 | num\_\_BCL2L1 | 0.060435 |
| COR-L311|MG-132 | 4 | num\_\_FGF18 | 0.057931 |
| COR-L311|MG-132 | 5 | num\_\_IKZF1 | 0.052158 |
| COR-L321|Nutlin-3a (-) | 1 | num\_\_BCL2L1 | 0.109921 |
| COR-L321|Nutlin-3a (-) | 2 | num\_\_IKZF1 | 0.064271 |
| COR-L321|Nutlin-3a (-) | 3 | num\_\_CARM1 | 0.050874 |
| COR-L321|Nutlin-3a (-) | 4 | num\_\_EEF2 | 0.045190 |
| COR-L321|Nutlin-3a (-) | 5 | num\_\_IL12RB1 | 0.037419 |
| CS1|Nutlin-3a (-) | 1 | num\_\_BCL2L1 | 0.097448 |
| CS1|Nutlin-3a (-) | 2 | num\_\_ELMO1 | 0.069313 |
| CS1|Nutlin-3a (-) | 3 | num\_\_IKZF1 | 0.060176 |
| CS1|Nutlin-3a (-) | 4 | num\_\_APTX | 0.053716 |
| CS1|Nutlin-3a (-) | 5 | num\_\_CARM1 | 0.049422 |
| D-247MG|5-Fluorouracil | 1 | num\_\_BCL2L1 | 0.091541 |
| D-247MG|5-Fluorouracil | 2 | num\_\_IKZF1 | 0.059684 |
| D-247MG|5-Fluorouracil | 3 | num\_\_CD81 | 0.052167 |
| D-247MG|5-Fluorouracil | 4 | num\_\_CARM1 | 0.044736 |
| D-247MG|5-Fluorouracil | 5 | num\_\_AGAP2 | 0.043533 |
| D-336MG|Staurosporine | 1 | num\_\_IKZF1 | 0.078156 |
| D-336MG|Staurosporine | 2 | num\_\_EEF2 | 0.068480 |
| D-336MG|Staurosporine | 3 | num\_\_BCL2L1 | 0.062512 |
| D-336MG|Staurosporine | 4 | num\_\_GSTM1 | 0.053635 |
| D-336MG|Staurosporine | 5 | num\_\_APTX | 0.051080 |
| D-423MG|MG-132 | 1 | num\_\_AGAP2 | 0.083326 |
| D-423MG|MG-132 | 2 | num\_\_APTX | 0.068949 |
| D-423MG|MG-132 | 3 | num\_\_BCL2L1 | 0.059845 |
| D-423MG|MG-132 | 4 | num\_\_IGFBP1 | 0.049843 |
| D-423MG|MG-132 | 5 | num\_\_IKZF1 | 0.049494 |
| DOHH-2|MG-132 | 1 | num\_\_IKZF1 | 0.270006 |
| DOHH-2|MG-132 | 2 | num\_\_DEF6 | 0.182608 |
| DOHH-2|MG-132 | 3 | num\_\_GRK6 | 0.077816 |
| DOHH-2|MG-132 | 4 | num\_\_EEF2 | 0.077606 |
| DOHH-2|MG-132 | 5 | num\_\_AGAP2 | 0.076098 |
| DiFi|MG-132 | 1 | num\_\_BCL2L1 | 0.113767 |
| DiFi|MG-132 | 2 | num\_\_EEF2 | 0.096293 |
| DiFi|MG-132 | 3 | num\_\_ASAP1 | 0.092021 |
| DiFi|MG-132 | 4 | num\_\_IKZF1 | 0.065916 |
| DiFi|MG-132 | 5 | num\_\_CD81 | 0.053021 |
| ES6|Pictilisib | 1 | num\_\_EEF2 | 0.064962 |
| ES6|Pictilisib | 2 | num\_\_CDC37 | 0.052782 |
| ES6|Pictilisib | 3 | num\_\_APTX | 0.049742 |
| ES6|Pictilisib | 4 | num\_\_ADCY9 | 0.041780 |
| ES6|Pictilisib | 5 | num\_\_ITGA3 | 0.041253 |
| EW-7|Pictilisib | 1 | num\_\_AGAP2 | 0.089180 |
| EW-7|Pictilisib | 2 | num\_\_BCL2L1 | 0.078351 |
| EW-7|Pictilisib | 3 | num\_\_ARHGAP4 | 0.070866 |
| EW-7|Pictilisib | 4 | num\_\_FGF18 | 0.052380 |
| EW-7|Pictilisib | 5 | num\_\_ITGA3 | 0.049650 |
| FADU|Olaparib | 1 | num\_\_IKZF1 | 0.087930 |
| FADU|Olaparib | 2 | num\_\_BCL2L1 | 0.071656 |
| FADU|Olaparib | 3 | num\_\_ELF1 | 0.054211 |
| FADU|Olaparib | 4 | num\_\_EEF2 | 0.052092 |
| FADU|Olaparib | 5 | num\_\_APTX | 0.049292 |
| GRANTA-519|Navitoclax | 1 | num\_\_IKZF1 | 0.152829 |
| GRANTA-519|Navitoclax | 2 | num\_\_DEF6 | 0.119975 |
| GRANTA-519|Navitoclax | 3 | num\_\_AGAP2 | 0.075878 |
| GRANTA-519|Navitoclax | 4 | num\_\_EEF2 | 0.073263 |
| GRANTA-519|Navitoclax | 5 | num\_\_GNAI3 | 0.065334 |
| HARA|Staurosporine | 1 | num\_\_IKZF1 | 0.075753 |
| HARA|Staurosporine | 2 | num\_\_BCL2L1 | 0.064822 |
| HARA|Staurosporine | 3 | num\_\_HDAC11 | 0.043470 |
| HARA|Staurosporine | 4 | num\_\_IL12RB1 | 0.038706 |
| HARA|Staurosporine | 5 | num\_\_CARM1 | 0.035297 |
| HCC-15|PD0325901 | 1 | num\_\_BCL2L1 | 0.136099 |
| HCC-15|PD0325901 | 2 | num\_\_IKZF1 | 0.103261 |
| HCC-15|PD0325901 | 3 | num\_\_EEF2 | 0.069388 |
| HCC-15|PD0325901 | 4 | num\_\_CDC37 | 0.052070 |
| HCC-15|PD0325901 | 5 | num\_\_CARM1 | 0.050874 |
| HCC1143|Nutlin-3a (-) | 1 | num\_\_IKZF1 | 0.115032 |
| HCC1143|Nutlin-3a (-) | 2 | num\_\_EEF2 | 0.055374 |
| HCC1143|Nutlin-3a (-) | 3 | num\_\_IL12RB1 | 0.045805 |
| HCC1143|Nutlin-3a (-) | 4 | num\_\_AGAP2 | 0.045693 |
| HCC1143|Nutlin-3a (-) | 5 | num\_\_EXOC2 | 0.045145 |
| HDQ-P1|PD173074 | 1 | num\_\_BCL2L1 | 0.072831 |
| HDQ-P1|PD173074 | 2 | num\_\_IGFBP1 | 0.065498 |
| HDQ-P1|PD173074 | 3 | num\_\_EEF2 | 0.064447 |
| HDQ-P1|PD173074 | 4 | num\_\_EEF2K | 0.057108 |
| HDQ-P1|PD173074 | 5 | num\_\_IKZF1 | 0.056498 |
| HLE|Navitoclax | 1 | num\_\_EEF2 | 0.074006 |
| HLE|Navitoclax | 2 | num\_\_BCL2L1 | 0.070156 |
| HLE|Navitoclax | 3 | num\_\_IKZF1 | 0.060218 |
| HLE|Navitoclax | 4 | num\_\_APTX | 0.052619 |
| HLE|Navitoclax | 5 | num\_\_CDC37 | 0.051241 |
| HO-1-N-1|MK-2206 | 1 | num\_\_BCL2L1 | 0.104826 |
| HO-1-N-1|MK-2206 | 2 | num\_\_IKZF1 | 0.097610 |
| HO-1-N-1|MK-2206 | 3 | num\_\_CKS1B | 0.089106 |
| HO-1-N-1|MK-2206 | 4 | num\_\_ELF1 | 0.067892 |
| HO-1-N-1|MK-2206 | 5 | num\_\_GPC1 | 0.051375 |
| HO-1-u-1|Nutlin-3a (-) | 1 | num\_\_BCL2L1 | 0.097285 |
| HO-1-u-1|Nutlin-3a (-) | 2 | num\_\_IKZF1 | 0.086195 |
| HO-1-u-1|Nutlin-3a (-) | 3 | num\_\_IL12RB1 | 0.045400 |
| HO-1-u-1|Nutlin-3a (-) | 4 | num\_\_CARM1 | 0.044736 |
| HO-1-u-1|Nutlin-3a (-) | 5 | num\_\_EEF2 | 0.041151 |
| HPAC|Pictilisib | 1 | num\_\_IGFBP1 | 0.099705 |
| HPAC|Pictilisib | 2 | num\_\_IKZF1 | 0.087527 |
| HPAC|Pictilisib | 3 | num\_\_EEF2 | 0.083951 |
| HPAC|Pictilisib | 4 | num\_\_CKS1B | 0.083291 |
| HPAC|Pictilisib | 5 | num\_\_APTX | 0.080180 |
| HPAF-II|Docetaxel | 1 | num\_\_BCL2L1 | 0.156455 |
| HPAF-II|Docetaxel | 2 | num\_\_IKZF1 | 0.080052 |
| HPAF-II|Docetaxel | 3 | num\_\_APTX | 0.078030 |
| HPAF-II|Docetaxel | 4 | num\_\_IGFBP1 | 0.075263 |
| HPAF-II|Docetaxel | 5 | num\_\_EEF2 | 0.072364 |
| HT55|PD173074 | 1 | num\_\_EEF2 | 0.105616 |
| HT55|PD173074 | 2 | num\_\_BCL2L1 | 0.082505 |
| HT55|PD173074 | 3 | num\_\_DDB2 | 0.072480 |
| HT55|PD173074 | 4 | num\_\_IKZF1 | 0.068484 |
| HT55|PD173074 | 5 | num\_\_ELF1 | 0.067892 |
| HuH-7|MK-2206 | 1 | num\_\_BCL2L1 | 0.122765 |
| HuH-7|MK-2206 | 2 | num\_\_IKZF1 | 0.083326 |
| HuH-7|MK-2206 | 3 | num\_\_GSTM1 | 0.081485 |
| HuH-7|MK-2206 | 4 | num\_\_IGFBP1 | 0.076067 |
| HuH-7|MK-2206 | 5 | num\_\_APTX | 0.063124 |
| IM-9|Palbociclib | 1 | num\_\_IKZF1 | 0.262861 |
| IM-9|Palbociclib | 2 | num\_\_DEF6 | 0.166862 |
| IM-9|Palbociclib | 3 | num\_\_AGAP2 | 0.083399 |
| IM-9|Palbociclib | 4 | num\_\_BAX | 0.079332 |
| IM-9|Palbociclib | 5 | num\_\_CKS1B | 0.075804 |
| IPC-298|Camptothecin | 1 | num\_\_EEF2 | 0.071476 |
| IPC-298|Camptothecin | 2 | num\_\_BCL2L1 | 0.049999 |
| IPC-298|Camptothecin | 3 | num\_\_IKZF1 | 0.047301 |
| IPC-298|Camptothecin | 4 | num\_\_FGF18 | 0.046773 |
| IPC-298|Camptothecin | 5 | num\_\_ITGA3 | 0.046718 |
| JHH-4|Nutlin-3a (-) | 1 | num\_\_BCL2L1 | 0.076895 |
| JHH-4|Nutlin-3a (-) | 2 | num\_\_IKZF1 | 0.067681 |
| JHH-4|Nutlin-3a (-) | 3 | num\_\_CARM1 | 0.050874 |
| JHH-4|Nutlin-3a (-) | 4 | num\_\_IL12RB1 | 0.045682 |
| JHH-4|Nutlin-3a (-) | 5 | num\_\_APTX | 0.045197 |
| JHH-6|Pictilisib | 1 | num\_\_EEF2K | 0.110633 |
| JHH-6|Pictilisib | 2 | num\_\_IKZF1 | 0.091296 |
| JHH-6|Pictilisib | 3 | num\_\_BCL2L1 | 0.084800 |
| JHH-6|Pictilisib | 4 | num\_\_EEF2 | 0.063982 |
| JHH-6|Pictilisib | 5 | num\_\_IGFBP1 | 0.063114 |
| JHH-7|Pictilisib | 1 | num\_\_EEF2 | 0.088255 |
| JHH-7|Pictilisib | 2 | num\_\_APTX | 0.075528 |
| JHH-7|Pictilisib | 3 | num\_\_IGFBP1 | 0.074943 |
| JHH-7|Pictilisib | 4 | num\_\_IKZF1 | 0.061124 |
| JHH-7|Pictilisib | 5 | num\_\_HDAC11 | 0.041168 |
| KMRC-20|Olaparib | 1 | num\_\_EEF2K | 0.070748 |
| KMRC-20|Olaparib | 2 | num\_\_EEF2 | 0.066412 |
| KMRC-20|Olaparib | 3 | num\_\_IKZF1 | 0.065476 |
| KMRC-20|Olaparib | 4 | num\_\_CDC37 | 0.058652 |
| KMRC-20|Olaparib | 5 | num\_\_DDB2 | 0.041644 |
| KP-1N|Camptothecin | 1 | num\_\_BCL2L1 | 0.108681 |
| KP-1N|Camptothecin | 2 | num\_\_IKZF1 | 0.077974 |
| KP-1N|Camptothecin | 3 | num\_\_IRAK1 | 0.050269 |
| KP-1N|Camptothecin | 4 | num\_\_CARM1 | 0.049422 |
| KP-1N|Camptothecin | 5 | num\_\_F10 | 0.040727 |
| KU-19-19|Pictilisib | 1 | num\_\_BCL2L1 | 0.070156 |
| KU-19-19|Pictilisib | 2 | num\_\_EEF2 | 0.061202 |
| KU-19-19|Pictilisib | 3 | num\_\_GSTM1 | 0.060032 |
| KU-19-19|Pictilisib | 4 | num\_\_IKZF1 | 0.055587 |
| KU-19-19|Pictilisib | 5 | num\_\_HBP1 | 0.039296 |
| KYSE-150|Palbociclib | 1 | num\_\_IKZF1 | 0.102259 |
| KYSE-150|Palbociclib | 2 | num\_\_ITGA3 | 0.063360 |
| KYSE-150|Palbociclib | 3 | num\_\_FGF18 | 0.063102 |
| KYSE-150|Palbociclib | 4 | num\_\_BCL2L1 | 0.055824 |
| KYSE-150|Palbociclib | 5 | num\_\_IL12RB1 | 0.045029 |
| KYSE-450|Nutlin-3a (-) | 1 | num\_\_IKZF1 | 0.072900 |
| KYSE-450|Nutlin-3a (-) | 2 | num\_\_BCL2L1 | 0.062249 |
| KYSE-450|Nutlin-3a (-) | 3 | num\_\_AREG | 0.053925 |
| KYSE-450|Nutlin-3a (-) | 4 | num\_\_EEF2 | 0.044434 |
| KYSE-450|Nutlin-3a (-) | 5 | num\_\_CARM1 | 0.039983 |
| KYSE-510|Nutlin-3a (-) | 1 | num\_\_BCL2L1 | 0.073597 |
| KYSE-510|Nutlin-3a (-) | 2 | num\_\_EEF2 | 0.063052 |
| KYSE-510|Nutlin-3a (-) | 3 | num\_\_IKZF1 | 0.061316 |
| KYSE-510|Nutlin-3a (-) | 4 | num\_\_HDAC11 | 0.039939 |
| KYSE-510|Nutlin-3a (-) | 5 | num\_\_CARM1 | 0.037407 |
| KYSE-70|Nutlin-3a (-) | 1 | num\_\_BRIP1 | 0.087726 |
| KYSE-70|Nutlin-3a (-) | 2 | num\_\_BEX3 | 0.077319 |
| KYSE-70|Nutlin-3a (-) | 3 | num\_\_BCL2L1 | 0.073299 |
| KYSE-70|Nutlin-3a (-) | 4 | num\_\_IKZF1 | 0.051057 |
| KYSE-70|Nutlin-3a (-) | 5 | num\_\_GNAI3 | 0.049185 |
| LU-65|Camptothecin | 1 | num\_\_IKZF1 | 0.059709 |
| LU-65|Camptothecin | 2 | num\_\_BCL2L1 | 0.058397 |
| LU-65|Camptothecin | 3 | num\_\_ITGA3 | 0.050662 |
| LU-65|Camptothecin | 4 | num\_\_EEF2 | 0.043656 |
| LU-65|Camptothecin | 5 | num\_\_AGAP2 | 0.039520 |
| M059J|PD0325901 | 1 | num\_\_BCL2L1 | 0.106009 |
| M059J|PD0325901 | 2 | num\_\_IKZF1 | 0.086204 |
| M059J|PD0325901 | 3 | num\_\_IRAK1 | 0.051509 |
| M059J|PD0325901 | 4 | num\_\_CARM1 | 0.049422 |
| M059J|PD0325901 | 5 | num\_\_AGAP2 | 0.046442 |
| MDA-MB-231|Staurosporine | 1 | num\_\_BCL2L1 | 0.141257 |
| MDA-MB-231|Staurosporine | 2 | num\_\_IKZF1 | 0.099942 |
| MDA-MB-231|Staurosporine | 3 | num\_\_EEF2 | 0.066456 |
| MDA-MB-231|Staurosporine | 4 | num\_\_HDAC11 | 0.055798 |
| MDA-MB-231|Staurosporine | 5 | num\_\_CARM1 | 0.045101 |
| MDA-MB-453|PD173074 | 1 | num\_\_EEF2 | 0.110775 |
| MDA-MB-453|PD173074 | 2 | num\_\_IKZF1 | 0.097083 |
| MDA-MB-453|PD173074 | 3 | num\_\_CASP9 | 0.080381 |
| MDA-MB-453|PD173074 | 4 | num\_\_FGF18 | 0.047831 |
| MDA-MB-453|PD173074 | 5 | num\_\_HDAC11 | 0.041839 |
| ME-1|Olaparib | 1 | num\_\_IKZF1 | 0.279435 |
| ME-1|Olaparib | 2 | num\_\_DEF6 | 0.144965 |
| ME-1|Olaparib | 3 | num\_\_AGAP2 | 0.075848 |
| ME-1|Olaparib | 4 | num\_\_ELMO1 | 0.061858 |
| ME-1|Olaparib | 5 | num\_\_ITGA3 | 0.060434 |
| MFE-319|MK-2206 | 1 | num\_\_BCL2L1 | 0.103754 |
| MFE-319|MK-2206 | 2 | num\_\_IKZF1 | 0.097023 |
| MFE-319|MK-2206 | 3 | num\_\_IGFBP1 | 0.070748 |
| MFE-319|MK-2206 | 4 | num\_\_EEF2 | 0.060585 |
| MFE-319|MK-2206 | 5 | num\_\_CARM1 | 0.050874 |
| MHH-ES-1|PD0325901 | 1 | num\_\_BEX3 | 0.084358 |
| MHH-ES-1|PD0325901 | 2 | num\_\_EEF2 | 0.083432 |
| MHH-ES-1|PD0325901 | 3 | num\_\_ITGA3 | 0.081134 |
| MHH-ES-1|PD0325901 | 4 | num\_\_BCL2L1 | 0.051302 |
| MHH-ES-1|PD0325901 | 5 | num\_\_CTNNA1 | 0.041721 |
| ML-1|Olaparib | 1 | num\_\_BCL2L1 | 0.077637 |
| ML-1|Olaparib | 2 | num\_\_EEF2 | 0.069560 |
| ML-1|Olaparib | 3 | num\_\_BEX3 | 0.067784 |
| ML-1|Olaparib | 4 | num\_\_APTX | 0.067542 |
| ML-1|Olaparib | 5 | num\_\_IKZF1 | 0.056962 |
| MOLM-13|Palbociclib | 1 | num\_\_IKZF1 | 0.336059 |
| MOLM-13|Palbociclib | 2 | num\_\_DEF6 | 0.176303 |
| MOLM-13|Palbociclib | 3 | num\_\_BIRC3 | 0.108329 |
| MOLM-13|Palbociclib | 4 | num\_\_GRK6 | 0.095962 |
| MOLM-13|Palbociclib | 5 | num\_\_ARHGAP4 | 0.092926 |
| MOLT-13|Docetaxel | 1 | num\_\_IKZF1 | 0.307962 |
| MOLT-13|Docetaxel | 2 | num\_\_DEF6 | 0.143325 |
| MOLT-13|Docetaxel | 3 | num\_\_AGAP2 | 0.078032 |
| MOLT-13|Docetaxel | 4 | num\_\_GRK6 | 0.072631 |
| MOLT-13|Docetaxel | 5 | num\_\_ELMO1 | 0.065317 |
| MS-1|5-Fluorouracil | 1 | num\_\_EEF2 | 0.119986 |
| MS-1|5-Fluorouracil | 2 | num\_\_BID | 0.068920 |
| MS-1|5-Fluorouracil | 3 | num\_\_ITGA3 | 0.064635 |
| MS-1|5-Fluorouracil | 4 | num\_\_BIRC3 | 0.058676 |
| MS-1|5-Fluorouracil | 5 | num\_\_IKZF1 | 0.055789 |
| NB17|Staurosporine | 1 | num\_\_EEF2 | 0.117009 |
| NB17|Staurosporine | 2 | num\_\_AGAP2 | 0.080576 |
| NB17|Staurosporine | 3 | num\_\_ITGA3 | 0.064897 |
| NB17|Staurosporine | 4 | num\_\_BIRC3 | 0.055393 |
| NB17|Staurosporine | 5 | num\_\_ELMO1 | 0.044662 |
| NCI-H196|Staurosporine | 1 | num\_\_ATP6AP2 | 0.124522 |
| NCI-H196|Staurosporine | 2 | num\_\_BID | 0.095600 |
| NCI-H196|Staurosporine | 3 | num\_\_IKZF1 | 0.088565 |
| NCI-H196|Staurosporine | 4 | num\_\_BCL2L1 | 0.075903 |
| NCI-H196|Staurosporine | 5 | num\_\_BEX3 | 0.062952 |
| NCI-H2009|Docetaxel | 1 | num\_\_IKZF1 | 0.069936 |
| NCI-H2009|Docetaxel | 2 | num\_\_EEF2 | 0.052884 |
| NCI-H2009|Docetaxel | 3 | num\_\_FGF18 | 0.047654 |
| NCI-H2009|Docetaxel | 4 | num\_\_IL12RB1 | 0.034342 |
| NCI-H2009|Docetaxel | 5 | num\_\_CARM1 | 0.033792 |
| NCI-H2023|5-Fluorouracil | 1 | num\_\_BCL2L1 | 0.069705 |
| NCI-H2023|5-Fluorouracil | 2 | num\_\_IKZF1 | 0.063449 |
| NCI-H2023|5-Fluorouracil | 3 | num\_\_EEF2 | 0.063307 |
| NCI-H2023|5-Fluorouracil | 4 | num\_\_APTX | 0.059701 |
| NCI-H2023|5-Fluorouracil | 5 | num\_\_IGFBP1 | 0.059104 |
| NCI-H226|PD173074 | 1 | num\_\_IRAK1 | 0.112633 |
| NCI-H226|PD173074 | 2 | num\_\_APTX | 0.096177 |
| NCI-H226|PD173074 | 3 | num\_\_DLG1 | 0.093028 |
| NCI-H226|PD173074 | 4 | num\_\_CTNNA1 | 0.065814 |
| NCI-H226|PD173074 | 5 | num\_\_ITGA3 | 0.063549 |
| NCI-H2291|5-Fluorouracil | 1 | num\_\_BCL2L1 | 0.144627 |
| NCI-H2291|5-Fluorouracil | 2 | num\_\_IKZF1 | 0.104837 |
| NCI-H2291|5-Fluorouracil | 3 | num\_\_APTX | 0.072696 |
| NCI-H2291|5-Fluorouracil | 4 | num\_\_IGFBP1 | 0.065330 |
| NCI-H2291|5-Fluorouracil | 5 | num\_\_EEF2 | 0.064738 |
| NCI-H2369|Pictilisib | 1 | num\_\_ATP6AP2 | 0.213229 |
| NCI-H2369|Pictilisib | 2 | num\_\_BCL2L1 | 0.123756 |
| NCI-H2369|Pictilisib | 3 | num\_\_EEF2 | 0.080452 |
| NCI-H2369|Pictilisib | 4 | num\_\_GNAI3 | 0.067612 |
| NCI-H2369|Pictilisib | 5 | num\_\_EGLN1 | 0.062487 |
| NCI-H2452|Docetaxel | 1 | num\_\_BCL2L1 | 0.073299 |
| NCI-H2452|Docetaxel | 2 | num\_\_IKZF1 | 0.067261 |
| NCI-H2452|Docetaxel | 3 | num\_\_CLIP1 | 0.049883 |
| NCI-H2452|Docetaxel | 4 | num\_\_IL12RB1 | 0.043356 |
| NCI-H2452|Docetaxel | 5 | num\_\_CD81 | 0.043166 |
| NCI-H250|Palbociclib | 1 | num\_\_ATP6AP2 | 0.119076 |
| NCI-H250|Palbociclib | 2 | num\_\_BCL2L1 | 0.093860 |
| NCI-H250|Palbociclib | 3 | num\_\_EEF2 | 0.089198 |
| NCI-H250|Palbociclib | 4 | num\_\_BEX3 | 0.067321 |
| NCI-H250|Palbociclib | 5 | num\_\_ELMO1 | 0.062848 |
| NCI-H2591|Nutlin-3a (-) | 1 | num\_\_BCL2L1 | 0.126856 |
| NCI-H2591|Nutlin-3a (-) | 2 | num\_\_IRAK1 | 0.124657 |
| NCI-H2591|Nutlin-3a (-) | 3 | num\_\_HDAC11 | 0.082039 |
| NCI-H2591|Nutlin-3a (-) | 4 | num\_\_APTX | 0.075844 |
| NCI-H2591|Nutlin-3a (-) | 5 | num\_\_IKZF1 | 0.071024 |
| NCI-H28|5-Fluorouracil | 1 | num\_\_BCL2L1 | 0.147269 |
| NCI-H28|5-Fluorouracil | 2 | num\_\_CASP9 | 0.079485 |
| NCI-H28|5-Fluorouracil | 3 | num\_\_APTX | 0.075083 |
| NCI-H28|5-Fluorouracil | 4 | num\_\_IKZF1 | 0.075032 |
| NCI-H28|5-Fluorouracil | 5 | num\_\_EEF2 | 0.074929 |
| NCI-H28|Nutlin-3a (-) | 1 | num\_\_BCL2L1 | 0.147269 |
| NCI-H28|Nutlin-3a (-) | 2 | num\_\_CASP9 | 0.079485 |
| NCI-H28|Nutlin-3a (-) | 3 | num\_\_APTX | 0.075083 |
| NCI-H28|Nutlin-3a (-) | 4 | num\_\_IKZF1 | 0.075032 |
| NCI-H28|Nutlin-3a (-) | 5 | num\_\_EEF2 | 0.074929 |
| NCI-H358|5-Fluorouracil | 1 | num\_\_IKZF1 | 0.080282 |
| NCI-H358|5-Fluorouracil | 2 | num\_\_BCL2L1 | 0.079937 |
| NCI-H358|5-Fluorouracil | 3 | num\_\_AREG | 0.065979 |
| NCI-H358|5-Fluorouracil | 4 | num\_\_EEF2 | 0.056190 |
| NCI-H358|5-Fluorouracil | 5 | num\_\_IGFBP1 | 0.047693 |
| NCI-H747|5-Fluorouracil | 1 | num\_\_BCL2L1 | 0.133556 |
| NCI-H747|5-Fluorouracil | 2 | num\_\_IKZF1 | 0.079197 |
| NCI-H747|5-Fluorouracil | 3 | num\_\_IGFBP1 | 0.063060 |
| NCI-H747|5-Fluorouracil | 4 | num\_\_EEF2 | 0.061956 |
| NCI-H747|5-Fluorouracil | 5 | num\_\_CARM1 | 0.050874 |
| NCI-H841|Palbociclib | 1 | num\_\_BEX3 | 0.081056 |
| NCI-H841|Palbociclib | 2 | num\_\_EEF2 | 0.080950 |
| NCI-H841|Palbociclib | 3 | num\_\_IKZF1 | 0.071112 |
| NCI-H841|Palbociclib | 4 | num\_\_IGFBP1 | 0.059946 |
| NCI-H841|Palbociclib | 5 | num\_\_BCL2L1 | 0.059668 |
| NMC-G1|Staurosporine | 1 | num\_\_ITGA3 | 0.307838 |
| NMC-G1|Staurosporine | 2 | num\_\_BCL2L1 | 0.132777 |
| NMC-G1|Staurosporine | 3 | num\_\_IKZF1 | 0.093885 |
| NMC-G1|Staurosporine | 4 | num\_\_BEX3 | 0.090773 |
| NMC-G1|Staurosporine | 5 | num\_\_IGFBP1 | 0.087720 |
| NUGC-3|5-Fluorouracil | 1 | num\_\_BCL2L1 | 0.108517 |
| NUGC-3|5-Fluorouracil | 2 | num\_\_IKZF1 | 0.076386 |
| NUGC-3|5-Fluorouracil | 3 | num\_\_EEF2 | 0.067429 |
| NUGC-3|5-Fluorouracil | 4 | num\_\_AKT1S1 | 0.053426 |
| NUGC-3|5-Fluorouracil | 5 | num\_\_CARM1 | 0.050874 |
| NUGC-3|Staurosporine | 1 | num\_\_BCL2L1 | 0.108517 |
| NUGC-3|Staurosporine | 2 | num\_\_IKZF1 | 0.076386 |
| NUGC-3|Staurosporine | 3 | num\_\_EEF2 | 0.067429 |
| NUGC-3|Staurosporine | 4 | num\_\_AKT1S1 | 0.053426 |
| NUGC-3|Staurosporine | 5 | num\_\_CARM1 | 0.050874 |
| OACp4C|PD173074 | 1 | num\_\_EEF2 | 0.063019 |
| OACp4C|PD173074 | 2 | num\_\_IKZF1 | 0.062753 |
| OACp4C|PD173074 | 3 | num\_\_CD81 | 0.049187 |
| OACp4C|PD173074 | 4 | num\_\_CDC37 | 0.046473 |
| OACp4C|PD173074 | 5 | num\_\_IGFBP1 | 0.044005 |
| OVK-18|MK-2206 | 1 | num\_\_ITGA3 | 0.068080 |
| OVK-18|MK-2206 | 2 | num\_\_BEX3 | 0.062782 |
| OVK-18|MK-2206 | 3 | num\_\_AGAP2 | 0.056586 |
| OVK-18|MK-2206 | 4 | num\_\_IKZF1 | 0.052799 |
| OVK-18|MK-2206 | 5 | num\_\_BCL2L1 | 0.052624 |
| P12-ICHIKAWA|Staurosporine | 1 | num\_\_IKZF1 | 0.375940 |
| P12-ICHIKAWA|Staurosporine | 2 | num\_\_DEF6 | 0.191962 |
| P12-ICHIKAWA|Staurosporine | 3 | num\_\_GRK6 | 0.077816 |
| P12-ICHIKAWA|Staurosporine | 4 | num\_\_AGAP2 | 0.076625 |
| P12-ICHIKAWA|Staurosporine | 5 | num\_\_ELMO1 | 0.064987 |
| PA-1|Olaparib | 1 | num\_\_EEF2 | 0.123363 |
| PA-1|Olaparib | 2 | num\_\_BAX | 0.101528 |
| PA-1|Olaparib | 3 | num\_\_AGAP2 | 0.078056 |
| PA-1|Olaparib | 4 | num\_\_IKZF1 | 0.064018 |
| PA-1|Olaparib | 5 | num\_\_BCL2L1 | 0.058405 |
| PC-14|Staurosporine | 1 | num\_\_IKZF1 | 0.078195 |
| PC-14|Staurosporine | 2 | num\_\_BCL2L1 | 0.075428 |
| PC-14|Staurosporine | 3 | num\_\_EEF2 | 0.061909 |
| PC-14|Staurosporine | 4 | num\_\_IGFBP1 | 0.050179 |
| PC-14|Staurosporine | 5 | num\_\_HDAC11 | 0.046020 |
| PF-382|MK-2206 | 1 | num\_\_IKZF1 | 0.330875 |
| PF-382|MK-2206 | 2 | num\_\_DEF6 | 0.171319 |
| PF-382|MK-2206 | 3 | num\_\_AGAP2 | 0.094667 |
| PF-382|MK-2206 | 4 | num\_\_GRK6 | 0.077816 |
| PF-382|MK-2206 | 5 | num\_\_ELMO1 | 0.075038 |
| RKN|Olaparib | 1 | num\_\_EEF2K | 0.110633 |
| RKN|Olaparib | 2 | num\_\_IKZF1 | 0.081076 |
| RKN|Olaparib | 3 | num\_\_BCL2L1 | 0.070156 |
| RKN|Olaparib | 4 | num\_\_EEF2 | 0.053887 |
| RKN|Olaparib | 5 | num\_\_AGAP2 | 0.053746 |
| RKO|Palbociclib | 1 | num\_\_EEF2 | 0.136834 |
| RKO|Palbociclib | 2 | num\_\_BCL2L1 | 0.076474 |
| RKO|Palbociclib | 3 | num\_\_CKS1B | 0.074474 |
| RKO|Palbociclib | 4 | num\_\_BAX | 0.060058 |
| RKO|Palbociclib | 5 | num\_\_ELF1 | 0.052117 |
| ROS-50|Pictilisib | 1 | num\_\_IKZF1 | 0.139362 |
| ROS-50|Pictilisib | 2 | num\_\_GRK6 | 0.072631 |
| ROS-50|Pictilisib | 3 | num\_\_AGAP2 | 0.064169 |
| ROS-50|Pictilisib | 4 | num\_\_EEF2 | 0.063540 |
| ROS-50|Pictilisib | 5 | num\_\_GNAI3 | 0.063490 |
| SBC-5|Camptothecin | 1 | num\_\_BCL2L1 | 0.059845 |
| SBC-5|Camptothecin | 2 | num\_\_EEF2 | 0.058294 |
| SBC-5|Camptothecin | 3 | num\_\_AGAP2 | 0.049607 |
| SBC-5|Camptothecin | 4 | num\_\_BIRC3 | 0.042859 |
| SBC-5|Camptothecin | 5 | num\_\_IKZF1 | 0.042631 |
| SF268|5-Fluorouracil | 1 | num\_\_IKZF1 | 0.084965 |
| SF268|5-Fluorouracil | 2 | num\_\_IRAK1 | 0.074969 |
| SF268|5-Fluorouracil | 3 | num\_\_IGFBP1 | 0.057651 |
| SF268|5-Fluorouracil | 4 | num\_\_HDAC11 | 0.043397 |
| SF268|5-Fluorouracil | 5 | num\_\_ITGA3 | 0.036788 |
| SF268|Nutlin-3a (-) | 1 | num\_\_IKZF1 | 0.084965 |
| SF268|Nutlin-3a (-) | 2 | num\_\_IRAK1 | 0.074969 |
| SF268|Nutlin-3a (-) | 3 | num\_\_IGFBP1 | 0.057651 |
| SF268|Nutlin-3a (-) | 4 | num\_\_HDAC11 | 0.043397 |
| SF268|Nutlin-3a (-) | 5 | num\_\_ITGA3 | 0.036788 |
| SISO|Navitoclax | 1 | num\_\_APTX | 0.071665 |
| SISO|Navitoclax | 2 | num\_\_IKZF1 | 0.066475 |
| SISO|Navitoclax | 3 | num\_\_IGFBP1 | 0.062636 |
| SISO|Navitoclax | 4 | num\_\_CDC37 | 0.047905 |
| SISO|Navitoclax | 5 | num\_\_AREG | 0.043063 |
| SK-MEL-1|Camptothecin | 1 | num\_\_APTX | 0.110408 |
| SK-MEL-1|Camptothecin | 2 | num\_\_IKZF1 | 0.076814 |
| SK-MEL-1|Camptothecin | 3 | num\_\_BCL2L1 | 0.068026 |
| SK-MEL-1|Camptothecin | 4 | num\_\_HDAC11 | 0.049068 |
| SK-MEL-1|Camptothecin | 5 | num\_\_CPEB1 | 0.044704 |
| SK-MEL-28|PD173074 | 1 | num\_\_EEF2 | 0.077430 |
| SK-MEL-28|PD173074 | 2 | num\_\_BCL2L1 | 0.072831 |
| SK-MEL-28|PD173074 | 3 | num\_\_APTX | 0.068796 |
| SK-MEL-28|PD173074 | 4 | num\_\_IKZF1 | 0.061446 |
| SK-MEL-28|PD173074 | 5 | num\_\_HDAC11 | 0.046429 |
| SK-MEL-3|Navitoclax | 1 | num\_\_IKZF1 | 0.079221 |
| SK-MEL-3|Navitoclax | 2 | num\_\_BCL2L1 | 0.072462 |
| SK-MEL-3|Navitoclax | 3 | num\_\_EEF2 | 0.055352 |
| SK-MEL-3|Navitoclax | 4 | num\_\_AGAP2 | 0.044197 |
| SK-MEL-3|Navitoclax | 5 | num\_\_ITGA3 | 0.040604 |
| SK-N-FI|Camptothecin | 1 | num\_\_AGAP2 | 0.081230 |
| SK-N-FI|Camptothecin | 2 | num\_\_EEF2 | 0.068810 |
| SK-N-FI|Camptothecin | 3 | num\_\_BCL2L1 | 0.064486 |
| SK-N-FI|Camptothecin | 4 | num\_\_IKZF1 | 0.055551 |
| SK-N-FI|Camptothecin | 5 | num\_\_HDAC11 | 0.052546 |
| SNU-C2B|Staurosporine | 1 | num\_\_BCL2L1 | 0.127933 |
| SNU-C2B|Staurosporine | 2 | num\_\_EEF2 | 0.094927 |
| SNU-C2B|Staurosporine | 3 | num\_\_IKZF1 | 0.066003 |
| SNU-C2B|Staurosporine | 4 | num\_\_AREG | 0.055100 |
| SNU-C2B|Staurosporine | 5 | num\_\_IGFBP1 | 0.046707 |
| SUP-B8|MK-2206 | 1 | num\_\_IKZF1 | 0.287257 |
| SUP-B8|MK-2206 | 2 | num\_\_DEF6 | 0.138050 |
| SUP-B8|MK-2206 | 3 | num\_\_EEF2 | 0.077606 |
| SUP-B8|MK-2206 | 4 | num\_\_ELMO1 | 0.064197 |
| SUP-B8|MK-2206 | 5 | num\_\_AGAP2 | 0.061448 |
| SW684|PD0325901 | 1 | num\_\_ITGA3 | 0.235901 |
| SW684|PD0325901 | 2 | num\_\_ATP6AP2 | 0.177800 |
| SW684|PD0325901 | 3 | num\_\_BCL2L1 | 0.122190 |
| SW684|PD0325901 | 4 | num\_\_EEF2 | 0.102047 |
| SW684|PD0325901 | 5 | num\_\_BID | 0.098487 |
| T-T|Navitoclax | 1 | num\_\_IKZF1 | 0.082757 |
| T-T|Navitoclax | 2 | num\_\_EEF2 | 0.081428 |
| T-T|Navitoclax | 3 | num\_\_BID | 0.072607 |
| T-T|Navitoclax | 4 | num\_\_FGF18 | 0.071400 |
| T-T|Navitoclax | 5 | num\_\_GSTM1 | 0.068912 |
| T24|Olaparib | 1 | num\_\_BCL2L1 | 0.100076 |
| T24|Olaparib | 2 | num\_\_IKZF1 | 0.078753 |
| T24|Olaparib | 3 | num\_\_IRAK1 | 0.053959 |
| T24|Olaparib | 4 | num\_\_HDAC11 | 0.051677 |
| T24|Olaparib | 5 | num\_\_IGFBP1 | 0.050329 |
| U-266|Docetaxel | 1 | num\_\_IKZF1 | 0.148071 |
| U-266|Docetaxel | 2 | num\_\_IRAK1 | 0.077276 |
| U-266|Docetaxel | 3 | num\_\_EEF2 | 0.075129 |
| U-266|Docetaxel | 4 | num\_\_AGAP2 | 0.062338 |
| U-266|Docetaxel | 5 | num\_\_DEF6 | 0.059553 |
| UWB1.289|Staurosporine | 1 | num\_\_BCL2L1 | 0.135172 |
| UWB1.289|Staurosporine | 2 | num\_\_IKZF1 | 0.090849 |
| UWB1.289|Staurosporine | 3 | num\_\_APTX | 0.063366 |
| UWB1.289|Staurosporine | 4 | num\_\_EEF2 | 0.061413 |
| UWB1.289|Staurosporine | 5 | num\_\_CCND2 | 0.047138 |
| VMRC-MELG|Navitoclax | 1 | num\_\_ITGA3 | 0.168341 |
| VMRC-MELG|Navitoclax | 2 | num\_\_BCL2L1 | 0.103218 |
| VMRC-MELG|Navitoclax | 3 | num\_\_APTX | 0.079536 |
| VMRC-MELG|Navitoclax | 4 | num\_\_IKZF1 | 0.064154 |
| VMRC-MELG|Navitoclax | 5 | num\_\_ELMO1 | 0.059887 |
| WM278|Navitoclax | 1 | num\_\_EEF2 | 0.086869 |
| WM278|Navitoclax | 2 | num\_\_DDB2 | 0.065788 |
| WM278|Navitoclax | 3 | num\_\_EGLN1 | 0.062487 |
| WM278|Navitoclax | 4 | num\_\_APTX | 0.060068 |
| WM278|Navitoclax | 5 | num\_\_GNAI3 | 0.056970 |
| WSU-NHL|Palbociclib | 1 | num\_\_IKZF1 | 0.265554 |
| WSU-NHL|Palbociclib | 2 | num\_\_DEF6 | 0.148547 |
| WSU-NHL|Palbociclib | 3 | num\_\_GRK6 | 0.077816 |
| WSU-NHL|Palbociclib | 4 | num\_\_EEF2 | 0.066236 |
| WSU-NHL|Palbociclib | 5 | num\_\_AGAP2 | 0.065832 |
| YH-13|5-Fluorouracil | 1 | num\_\_BEX3 | 0.085514 |
| YH-13|5-Fluorouracil | 2 | num\_\_BCL2L1 | 0.072435 |
| YH-13|5-Fluorouracil | 3 | num\_\_EEF2 | 0.063734 |
| YH-13|5-Fluorouracil | 4 | num\_\_IKZF1 | 0.054791 |
| YH-13|5-Fluorouracil | 5 | num\_\_CARM1 | 0.044736 |
| YT|Staurosporine | 1 | num\_\_IKZF1 | 0.326117 |
| YT|Staurosporine | 2 | num\_\_DEF6 | 0.143386 |
| YT|Staurosporine | 3 | num\_\_BID | 0.080961 |
| YT|Staurosporine | 4 | num\_\_AGAP2 | 0.078812 |
| YT|Staurosporine | 5 | num\_\_BAX | 0.077408 |

**Table 5. Task 4 Least-Error Pair SHAP Contributions**

Description: Feature contributions for the drug–cell-line pair with the smallest prediction error.

Observation: Only a handful of genes explain the near-perfect estimate for that pair.

Conclusion: The regressor is most reliable where the experimental signal is clean.

|  |  |  |
| --- | --- | --- |
| Rank | Feature | Absolute\_SHAP |
| 1 | num\_\_BCL2L1 | 0.081477 |
| 2 | num\_\_EEF2 | 0.072085 |
| 3 | num\_\_IKZF1 | 0.063014 |
| 4 | num\_\_BEX3 | 0.062385 |
| 5 | num\_\_BID | 0.055235 |
| 6 | num\_\_CARM1 | 0.038349 |
| 7 | num\_\_ITGA3 | 0.036348 |
| 8 | num\_\_IL12RB1 | 0.034663 |
| 9 | num\_\_GSTM1 | 0.033656 |
| 10 | num\_\_HDAC11 | 0.027906 |

# 3. Runtime and Automation Summary

The experiment tracker recorded sub-second runtimes for every stage (≤0.31 s) thanks to cached datasets, parallel sweeps, and the SHAP fallbacks baked into the notebook. Checkpoints in `hw3\_outputs/checkpoints/` allow future reruns to resume instantly, while `experiment\_state.json` preserves per-step timing and memory deltas for audits.

# 4. Reflections & Next Steps

Building this workflow underscored how much leverage tight feedback loops provide: Polars keeps ingestion swift, joblib parallelises the sweeps, and SHAP turns raw feature importances into narratives I can defend. If this project grows toward production or larger cohorts, the natural extensions are GPU-accelerated boosting (à la RAPIDS) and a feature store to version engineered signals. For HW3, the notebook—and this report—capture every requirement in a reproducible, readable form.